Murat Osman Arcasoy | Scholars@Duke

Murat Osman Arcasoy
Professor of Medicine

Dr. Arcasoy's research interests include 1)The role of cytokines and cytokine receptors in hematopoietic commitment and lineage-specific differentiation 2) Mechanisms of tissue-specific expression of erythropoietin receptor (EPOR) gene and its role in lineage commitment and lineage-specific differentiation 3) Studies of the molecular basis of familial and congenital myeloproliferative disorders.4). Isolation of novel hematopoietic cytokine-responsive genes and study of their function and regulation 5). Characterization of novel non-hematopoietic functions of EPOR signaling

Dr. Arcasoy's laboratory has been studying the expression, regulation and function of the EPOR gene focusing on the function of naturally occuring mutations of the EPOR gene that result in primary familial and congenital polycythemia as well as the non-hematopoietic expression and functions of EPOR in vascular endothelium, macrophages, cardiac myocytes and cancer cells. We have also been studying global gene expression in erythroid cells from patients with polycythemia vera to better characterize the molecular signature of the disorder and develop new diagnostic tools.

Current Appointments & Affiliations

Professor of Medicine, Medicine, Hematology, Medicine 2016
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 2012

Contact Information

Duke Box 3912, Durham, NC 27710
Hosp South Trent Drive, Box 3912 DUMC, Durham, NC 27710
arcas001@mc.duke.edu (919) 684-5350

Background
Education, Training, & Certifications
- Fellow in Medical Oncology, Medicine, Yale University 1997 - 1998
- Hematology Fellow, Medicine, Yale University 1992 - 1993
- Chief Medical Resident, Medicine, State University of New York, Brooklyn 1991 - 1992
- Medical Resident, Medicine, State University of New York, Brooklyn 1988 - 1991
- M.D., Aegean University, School of Medicine (Turkey) 1987
Previous Appointments & Affiliations
- Associate Professor of Medicine, Medicine, Hematology, Medicine 2009 - 2016
- Associate Professor of Medicine, Medicine, Hematology, Medicine 2005 - 2009
- Assistant Professor of Medicine, Medicine, Hematology, Medicine 1999 - 2005
Recognition
In the News
- FEB 12, 2021 Duke Cancer Institute
  
  This Nurse Treated Cancer Patients for Years. Then Her Husband Became One.
Research
Selected Grants
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Mascarenhas, John, Heidi E. Kosiorek, Josef T. Prchal, Alessandro Rambaldi, Dmitriy Berenzon, Abdulraheem Yacoub, Claire N. Harrison, et al. “A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.” Blood 139, no. 19 (May 2022): 2931–41. https://doi.org/10.1182/blood.2021012743.
    Full Text
  - Talpaz, Moshe, Josef Prchal, Lawrence Afrin, Murat Arcasoy, Solomon Hamburg, Jason Clark, Deanna Kornacki, Philomena Colucci, and Srdan Verstovsek. “Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study.” Clin Lymphoma Myeloma Leuk 22, no. 5 (May 2022): 336–46. https://doi.org/10.1016/j.clml.2021.10.016.
    Full Text Link to Item
  - Price, Jeremy G., Donna Niedzwiecki, Taofik Oyekunle, Murat O. Arcasoy, Colin E. Champ, Chris R. Kelsey, Joseph K. Salama, and Michael J. Moravan. “Effective Pain Control With Very Low Dose Palliative Radiation Therapy for Patients With Multiple Myeloma With Uncomplicated Osseous Lesions.” Adv Radiat Oncol 6, no. 4 (2021): 100729. https://doi.org/10.1016/j.adro.2021.100729.
    Full Text Link to Item
  - Oh, Stephen T., Moshe Talpaz, Aaron T. Gerds, Vikas Gupta, Srdan Verstovsek, Ruben Mesa, Carole B. Miller, et al. “ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.” Blood Adv 4, no. 18 (September 22, 2020): 4282–91. https://doi.org/10.1182/bloodadvances.2020002662.
    Full Text Link to Item
  - Gowin, Krisstina, Karen Ballen, Kwang Woo Ahn, Zhen-Huan Hu, Haris Ali, Murat O. Arcasoy, Rebecca Devlin, et al. “Survival following allogeneic transplant in patients with myelofibrosis.” Blood Adv 4, no. 9 (May 12, 2020): 1965–73. https://doi.org/10.1182/bloodadvances.2019001084.
    Full Text Open Access Copy Link to Item
  - Arcasoy, Murat O. “Arterial thrombosis and second cancer in MPNs.” Blood 135, no. 5 (January 30, 2020): 301–2. https://doi.org/10.1182/blood.2019004627.
    Full Text Link to Item
  - Mascarenhas, J., H. Kosiorek, J. Prchal, A. Yacoub, D. Berenzon, M. R. Baer, E. Ritchie, et al. “A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.” Leukemia 33, no. 12 (December 2019): 2974–78. https://doi.org/10.1038/s41375-019-0524-7.
    Full Text Link to Item
  - Yacoub, Abdulraheem, John Mascarenhas, Heidi Kosiorek, Josef T. Prchal, Dmitry Berenzon, Maria R. Baer, Ellen Ritchie, et al. “Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.” Blood 134, no. 18 (October 31, 2019): 1498–1509. https://doi.org/10.1182/blood.2019000428.
    Full Text Link to Item
  - Gable, Dustin L., Valeriya Gaysinskaya, Christine C. Atik, C Conover Talbot, Byunghak Kang, Susan E. Stanley, Elizabeth W. Pugh, et al. “ZCCHC8, the nuclear exosome targeting component, is mutated in familial pulmonary fibrosis and is required for telomerase RNA maturation.” Genes Dev 33, no. 19–20 (October 1, 2019): 1381–96. https://doi.org/10.1101/gad.326785.119.
    Full Text Link to Item
  - Grainger, Brian T., Murat O. Arcasoy, and Christopher A. Kenedi. “Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: A systematic review of the literature.” Eur J Haematol 103, no. 4 (October 2019): 277–86. https://doi.org/10.1111/ejh.13285.
    Full Text Link to Item
  - Diep, Robert T., Kristin Corey, and Murat O. Arcasoy. “A novel nucleotide substitution in the 5' untranslated region of ANKRD26 gene is associated with inherited thrombocytopenia: a report of two new families.” Ann Hematol 98, no. 7 (July 2019): 1789–91. https://doi.org/10.1007/s00277-019-03632-y.
    Full Text Link to Item
  - Diep, Robert T., and Murat O. Arcasoy. “Pregnancy in patients with thrombocytopenia and absent radii (TAR) syndrome.” Ann Hematol 96, no. 9 (September 2017): 1589–90. https://doi.org/10.1007/s00277-017-3053-3.
    Full Text Link to Item
  - Verstovsek, Srdan, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, et al. “Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.” J Hematol Oncol 10, no. 1 (February 22, 2017): 55. https://doi.org/10.1186/s13045-017-0417-z.
    Full Text Link to Item
  - Abril, Maria K., Adam S. Barnett, Kara Wegermann, Eric Fountain, Andrew Strand, Benjamin M. Heyman, Britton A. Blough, et al. “Diagnosis of Capnocytophaga canimorsus Sepsis by Whole-Genome Next-Generation Sequencing.” Open Forum Infect Dis 3, no. 3 (September 2016): ofw144. https://doi.org/10.1093/ofid/ofw144.
    Full Text Open Access Copy Link to Item
  - Shanavas, Mohamed, Uday Popat, Laura C. Michaelis, Veena Fauble, Donal McLornan, Rebecca Klisovic, John Mascarenhas, et al. “Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.” Biol Blood Marrow Transplant 22, no. 3 (March 2016): 432–40. https://doi.org/10.1016/j.bbmt.2015.10.005.
    Full Text Link to Item
  - Lee, Grace, and Murat O. Arcasoy. “The clinical and laboratory evaluation of the patient with erythrocytosis.” European Journal of Internal Medicine 26, no. 5 (June 2015): 297–302. https://doi.org/10.1016/j.ejim.2015.03.007.
    Full Text
  - Stein, Brady L., Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, et al. “Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.” J Natl Compr Canc Netw 13, no. 4 (April 2015): 424–34. https://doi.org/10.6004/jnccn.2015.0058.
    Full Text Link to Item
  - Verstovsek, Srdan, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, et al. “Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.” Haematologica 100, no. 4 (April 2015): 479–88. https://doi.org/10.3324/haematol.2014.115840.
    Full Text Link to Item
  - Silhan, Leann L., Pali D. Shah, Daniel C. Chambers, Laurie D. Snyder, Gerdt C. Riise, Christa L. Wagner, Eva Hellström-Lindberg, et al. “Lung transplantation in telomerase mutation carriers with pulmonary fibrosis.” Eur Respir J 44, no. 1 (July 2014): 178–87. https://doi.org/10.1183/09031936.00060014.
    Full Text Link to Item
  - Mesa, Ruben A., Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard Levy, et al. “Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.” Haematologica 99, no. 2 (February 2014): 292–98. https://doi.org/10.3324/haematol.2013.087650.
    Full Text Link to Item
  - Mesa, R. A., J. -. J. Kiladjian, S. Verstovsek, H. K. Al-Ali, J. Gotlib, H. Gisslinger, R. Levy, et al. “Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.” Haematologica 99, no. 2 (2014): 291–98.
  - Verstovsek, Srdan, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, et al. “Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.” Haematologica 98, no. 12 (December 2013): 1865–71. https://doi.org/10.3324/haematol.2013.092155.
    Full Text Link to Item
  - Verstovsek, Srdan, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, et al. “The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.” Br J Haematol 161, no. 4 (May 2013): 508–16. https://doi.org/10.1111/bjh.12274.
    Full Text Link to Item
  - Reddi, Deepti M., Chuanyi M. Lu, George Fedoriw, Yen-Chun Liu, Frances F. Wang, Scott Ely, Elizabeth L. Boswell, et al. “Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens.” Am J Clin Pathol 138, no. 6 (December 2012): 855–66. https://doi.org/10.1309/AJCPOP7APGDT9JIU.
    Full Text Link to Item
  - Kumar, S. M., G. Zhang, B. C. Bastian, M. O. Arcasoy, P. Karande, A. Pushparajan, G. Acs, and X. Xu. “Erythropoietin receptor contributes to melanoma cell survival in vivo.” Oncogene 31, no. 13 (March 29, 2012): 1649–60. https://doi.org/10.1038/onc.2011.366.
    Full Text Link to Item
  - Verstovsek, Srdan, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, et al. “A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.” N Engl J Med 366, no. 9 (March 1, 2012): 799–807. https://doi.org/10.1056/NEJMoa1110557.
    Full Text Link to Item
  - Inrig, Jula K., Suzanne K. Bryskin, Uptal D. Patel, Murat Arcasoy, and Lynda A. Szczech. “Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors.” Bmc Nephrol 12 (December 12, 2011): 67. https://doi.org/10.1186/1471-2369-12-67.
    Full Text Link to Item
  - McKinney, Matthew, and Murat O. Arcasoy. “Erythropoietin for oncology supportive care.” Exp Cell Res 317, no. 9 (May 15, 2011): 1246–54. https://doi.org/10.1016/j.yexcr.2011.03.003.
    Full Text Link to Item
  - Rizzo, J Douglas, Melissa Brouwers, Patricia Hurley, Jerome Seidenfeld, Murat O. Arcasoy, Jerry L. Spivak, Charles L. Bennett, et al. “American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.” J Clin Oncol 28, no. 33 (November 20, 2010): 4996–5010. https://doi.org/10.1200/JCO.2010.29.2201.
    Full Text Link to Item
  - Rizzo, J Douglas, Melissa Brouwers, Patricia Hurley, Jerome Seidenfeld, Murat O. Arcasoy, Jerry L. Spivak, Charles L. Bennett, et al. “American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.” Blood 116, no. 20 (November 18, 2010): 4045–59. https://doi.org/10.1182/blood-2010-08-300541.
    Full Text Link to Item
  - Arcasoy, Murat O. “Non-erythroid effects of erythropoietin.” Haematologica 95, no. 11 (November 2010): 1803–5. https://doi.org/10.3324/haematol.2010.030213.
    Full Text Link to Item
  - Kransdorf, Evan P., and Murat O. Arcasoy. “Unraveling a sticky paradox.” Am J Med 123, no. 5 (May 2010): 417–19. https://doi.org/10.1016/j.amjmed.2010.01.003.
    Full Text Link to Item
  - Laubach, Jacob P., Ping Fu, Xiaohong Jiang, Kelly H. Salter, Anil Potti, and Murat O. Arcasoy. “Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.” Exp Hematol 37, no. 12 (December 2009): 1411–22. https://doi.org/10.1016/j.exphem.2009.09.009.
    Full Text Link to Item
  - Fu, Ping, Xiaohong Jiang, and Murat O. Arcasoy. “Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway.” Biochem Biophys Res Commun 379, no. 3 (February 13, 2009): 696–701. https://doi.org/10.1016/j.bbrc.2008.12.146.
    Full Text Link to Item
  - Pilon, Andre M., Murat O. Arcasoy, Holly K. Dressman, Serena E. Vayda, Yelena D. Maksimova, Jose I. Sangerman, Patrick G. Gallagher, and David M. Bodine. “Failure of terminal erythroid differentiation in EKLF-deficient mice is associated with cell cycle perturbation and reduced expression of E2F2.” Mol Cell Biol 28, no. 24 (December 2008): 7394–7401. https://doi.org/10.1128/MCB.01087-08.
    Full Text Link to Item
  - Arcasoy, Murat O. “Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives.” Clin Cancer Res 14, no. 15 (August 1, 2008): 4685–90. https://doi.org/10.1158/1078-0432.CCR-08-0264.
    Full Text Link to Item
  - O’Shea, Susan I., Murat O. Arcasoy, Gregory Samsa, Sandra E. Cummings, Elizabeth H. Thames, Richard S. Surwit, and Thomas L. Ortel. “Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation.” J Thromb Thrombolysis 26, no. 1 (August 2008): 14–21. https://doi.org/10.1007/s11239-007-0068-y.
    Full Text Link to Item
  - Arcasoy, Murat O. “Erythropoiesis-stimulating agents in cancer.” J Clin Oncol 26, no. 18 (June 20, 2008): 3097–98. https://doi.org/10.1200/JCO.2008.16.0531.
    Full Text Link to Item
  - Arcasoy, Murat O. “The non-haematopoietic biological effects of erythropoietin.” Br J Haematol 141, no. 1 (April 2008): 14–31. https://doi.org/10.1111/j.1365-2141.2008.07014.x.
    Full Text Link to Item
  - Hardee, Matthew E., Yiting Cao, Ping Fu, Xiaohong Jiang, Yulin Zhao, Zahid N. Rabbani, Zeljko Vujaskovic, Mark W. Dewhirst, and Murat O. Arcasoy. “Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.” Plos One 2, no. 6 (June 20, 2007): e549. https://doi.org/10.1371/journal.pone.0000549.
    Full Text Link to Item
  - Arcasoy, Murat O., and Jon P. Gockerman. “Aplastic anaemia as an autoimmune complication of thymoma.” Br J Haematol 137, no. 4 (May 2007): 272. https://doi.org/10.1111/j.1365-2141.2007.06523.x.
    Full Text Link to Item
  - Fu, Ping, and Murat O. Arcasoy. “Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis.” Biochem Biophys Res Commun 354, no. 2 (March 9, 2007): 372–78. https://doi.org/10.1016/j.bbrc.2007.01.044.
    Full Text Link to Item
  - Martin, Mike G., and Murat O. Arcasoy. “Deferasirox versus deferoxamine.” Blood 108, no. 2 (July 15, 2006): 774–75. https://doi.org/10.1182/blood-2006-02-002436.
    Full Text Link to Item
  - Hardee, Matthew E., Zahid N. Rabbani, Murat O. Arcasoy, John P. Kirkpatrick, Zeljko Vujaskovic, Mark W. Dewhirst, and Kimberly L. Blackwell. “Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity.” Mol Cancer Ther 5, no. 2 (February 2006): 356–61. https://doi.org/10.1158/1535-7163.MCT-05-0196.
    Full Text Link to Item
  - Hardee, Matthew E., Murat O. Arcasoy, Kimberly L. Blackwell, John P. Kirkpatrick, and Mark W. Dewhirst. “Erythropoietin biology in cancer.” Clin Cancer Res 12, no. 2 (January 15, 2006): 332–39. https://doi.org/10.1158/1078-0432.CCR-05-1771.
    Full Text Link to Item
  - Hanlon, Paul R., Ping Fu, Gary L. Wright, Charles Steenbergen, Murat O. Arcasoy, and Elizabeth Murphy. “Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling.” Faseb J 19, no. 10 (August 2005): 1323–25. https://doi.org/10.1096/fj.04-3545fje.
    Full Text Link to Item
  - Arcasoy, Murat O., and Xiaohong Jiang. “Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor.” Br J Haematol 130, no. 1 (July 2005): 121–29. https://doi.org/10.1111/j.1365-2141.2005.05580.x.
    Full Text Link to Item
  - Arcasoy, Murat O., and Aysen F. Karayal. “Erythropoietin hypersensitivity in primary familial and congenital polycythemia: role of tyrosines Y285 and Y344 in erythropoietin receptor cytoplasmic domain.” Biochim Biophys Acta 1740, no. 1 (April 15, 2005): 17–28. https://doi.org/10.1016/j.bbadis.2005.03.003.
    Full Text Link to Item
  - Arcasoy, Murat O., Khalid Amin, Robin T. Vollmer, Xiaohong Jiang, Wendy Demark-Wahnefried, and Zishan A. Haroon. “Erythropoietin and erythropoietin receptor expression in human prostate cancer.” Mod Pathol 18, no. 3 (March 2005): 421–30. https://doi.org/10.1038/modpathol.3800288.
    Full Text Link to Item
  - Wang, Lei, Murat O. Arcasoy, Stephanie S. Watowich, and Bernard G. Forget. “Cytokine signals through STAT3 promote expression of granulocyte secondary granule proteins in 32D cells.” Exp Hematol 33, no. 3 (March 2005): 308–17. https://doi.org/10.1016/j.exphem.2004.11.014.
    Full Text Link to Item
  - Arcasoy, Murat O., and Nelson J. Chao. “T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil.” Am J Hematol 78, no. 2 (February 2005): 161–63. https://doi.org/10.1002/ajh.20237.
    Full Text Link to Item
  - Arcasoy, Murat O., Khalid Amin, Shu-Chuan Chou, Zishan A. Haroon, Mahesh Varia, and James A. Raleigh. “Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia.” Clin Cancer Res 11, no. 1 (January 1, 2005): 20–27.
    Link to Item
  - Arcasoy, Murat O., Don C. Rockey, and Michael A. Heneghan. “Pure red cell aplasia following pegylated interferon alpha treatment.” Am J Med 117, no. 8 (October 15, 2004): 619–20. https://doi.org/10.1016/j.amjmed.2004.04.023.
    Full Text Link to Item
  - Wright, Gary L., Paul Hanlon, Khalid Amin, Charles Steenbergen, Elizabeth Murphy, and Murat O. Arcasoy. “Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury.” Faseb J 18, no. 9 (June 2004): 1031–33. https://doi.org/10.1096/fj.03-1289fje.
    Full Text Link to Item
  - Collins, Timothy S., and Murat O. Arcasoy. “Iron overload due to X-linked sideroblastic anemia in an African American man.” Am J Med 116, no. 7 (April 1, 2004): 501–2. https://doi.org/10.1016/j.amjmed.2003.10.032.
    Full Text Link to Item
  - Haroon, Zishan A., Khalid Amin, Xiaohong Jiang, and Murat O. Arcasoy. “A novel role for erythropoietin during fibrin-induced wound-healing response.” Am J Pathol 163, no. 3 (September 2003): 993–1000. https://doi.org/10.1016/S0002-9440(10)63459-1.
    Full Text Link to Item
  - Arcasoy, Murat O., Xiaohong Jiang, and Zishan A. Haroon. “Expression of erythropoietin receptor splice variants in human cancer.” Biochem Biophys Res Commun 307, no. 4 (August 8, 2003): 999–1007. https://doi.org/10.1016/s0006-291x(03)01303-2.
    Full Text Link to Item
  - Arcasoy, Murat O., Khalid Amin, Aysen F. Karayal, Shu-Chuan Chou, James A. Raleigh, Mahesh A. Varia, and Zishan A. Haroon. “Functional significance of erythropoietin receptor expression in breast cancer.” Lab Invest 82, no. 7 (July 2002): 911–18. https://doi.org/10.1097/01.lab.0000020415.72863.40.
    Full Text Link to Item
  - Burns, Suzanne, Murat O. Arcasoy, Li Li, Elizabeth Kurian, Katri Selander, Peter D. Emanuel, and Kevin W. Harris. “Purification and characterization of the yeast-expressed erythropoietin mutant Epo (R103A), a specific inhibitor of human primary hematopoietic cell erythropoiesis.” Blood 99, no. 12 (June 15, 2002): 4400–4405. https://doi.org/10.1182/blood.v99.12.4400.
    Full Text Link to Item
  - Arcasoy, Murat O., Aysen F. Karayal, Harvey M. Segal, Joseph G. Sinning, and Bernard G. Forget. “A novel mutation in the erythropoietin receptor gene is associated with familial erythrocytosis.” Blood 99, no. 8 (April 15, 2002): 3066–69. https://doi.org/10.1182/blood.v99.8.3066.
    Full Text Link to Item
  - Arcasoy, M. O., N. A. Maun, L. Perez, B. G. Forget, and N. Berliner. “Erythropoietin mediates terminal granulocytic differentiation of committed myeloid cells with ectopic erythropoietin receptor expression.” Eur J Haematol 67, no. 2 (August 2001): 77–87.
    Link to Item
  - Abdrashitova, N. F., and Y. A. Romanov. “Functional insufficiency of the system responsible for reactive oxygen species generation by blood neutrophils.” Bull Exp Biol Med 132, no. 2 (August 2001): 809–10. https://doi.org/10.1023/a:1013010818812.
    Full Text Link to Item
  - Arcasoy, M., N. Maun, L. Ferez, B. Forget, and N. Berliner. “Interchangeabelity of cytokine receptor signals during terminal myeloid differentiation: erythropoietin receptor (epor) signals support granulocytic differentiation and induction of myeloid gene expression.” Blood 96, no. 11 PART II (December 1, 2000).
  - Forget, B. G., B. A. Degan, and M. O. Arcasoy. “Familial polycythemia due to truncations of the erythropoietin receptor.” Trans Am Clin Climatol Assoc 111 (2000): 38–44.
    Link to Item
  - Arcasoy, M. O., and P. G. Gallagher. “Molecular diagnosis of hemoglobinopathies and other red blood cell disorders.” Semin Hematol 36, no. 4 (October 1999): 328–39.
    Link to Item
  - Arcasoy, M. O., K. W. Harris, and B. G. Forget. “A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation.” Exp Hematol 27, no. 1 (January 1999): 63–74. https://doi.org/10.1016/s0301-472x(98)00003-4.
    Full Text Link to Item
  - Harris, K. W., X. J. Hu, S. Schultz, M. O. Arcasoy, B. G. Forget, and N. Clare. “The distal cytoplasmic domain of the erythropoietin receptor induces granulocytic differentiation in 32D cells.” Blood 92, no. 4 (August 15, 1998): 1219–24.
    Link to Item
  - Arcasoy, M. O., B. A. Degar, K. W. Harris, and B. G. Forget. “Familial erythrocytosis associated with a short deletion in the erythropoietin receptor gene.” Blood 89, no. 12 (June 15, 1997): 4628–35.
    Link to Item
  - Arcasoy, M. O., M. Romana, M. E. Fabry, E. Skarpidi, R. L. Nagel, and B. G. Forget. “High levels of human gamma-globin gene expression in adult mice carrying a transgene of deletion-type hereditary persistence of fetal hemoglobin.” Mol Cell Biol 17, no. 4 (April 1997): 2076–89. https://doi.org/10.1128/MCB.17.4.2076.
    Full Text Link to Item
  - Arcasoy, M. O., and P. G. Gallagher. “Hematologic disorders and nonimmune hydrops fetalis.” Semin Perinatol 19, no. 6 (December 1995): 502–15. https://doi.org/10.1016/s0146-0005(05)80057-6.
    Full Text Link to Item
  - Mookerjee, B., M. O. Arcasoy, and G. F. Atweh. “Spontaneous delta- to beta-globin switching in K562 human leukemia cells.” Blood 79, no. 3 (February 1, 1992): 820–25.
    Link to Item
  - Hirshkowitz, M., I. Karacan, J. W. Howell, M. O. Arcasoy, and R. L. Williams. “Nocturnal penile tumescence in cigarette smokers with erectile dysfunction.” Urology 39, no. 2 (February 1992): 101–7. https://doi.org/10.1016/0090-4295(92)90263-v.
    Full Text Link to Item
  - Luo, X. N., M. O. Arcasoy, H. E. Brickner, S. Mistry, A. D. Schechter, and G. F. Atweh. “Regulated expression of p18, a major phosphoprotein of leukemic cells.” J Biol Chem 266, no. 31 (November 5, 1991): 21004–10.
    Link to Item
  - Hirshkowitz, M., I. Karacan, M. O. Arcasoy, G. Acik, E. M. Narter, and R. L. Williams. “Prevalence of sleep apnea in men with erectile dysfunction.” Urology 36, no. 3 (September 1990): 232–34. https://doi.org/10.1016/0090-4295(90)80262-l.
    Full Text Link to Item
  - Hirshkowitz, M., I. Karacan, M. O. Arcasoy, G. Acik, and R. L. Williams. “The prevalence of periodic limb movements during sleep in men with erectile dysfunction.” Biol Psychiatry 26, no. 5 (September 1989): 541–44. https://doi.org/10.1016/0006-3223(89)90077-2.
    Full Text Link to Item
- Book Sections
  - Arcasoy, M. O. “Anemia in the Patient with Cancer.” In Anemia: Pathophysiology, Diagnosis, and Management, 172–78, 2018. https://doi.org/10.1017/9781108586900.025.
    Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

In the News

Selected Grants

Selected Publications

Academic Articles

Book Sections